Kaplan–Meier analyses of overall and relapse-free survival in ER+/HER2+ breast cancer patients revealed that HK2 high-expressing tumors are characterized by worse prognosis, independently of HER2, ESR1 and proliferation status measured using MKI67 levels. This evidence concerns the gene ERBB2 and breast carcinoma.